9 results about "Dose dumping" patented technology

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention relates to the technical field of pharmaceutical preparations, and discloses a nifedipine controlled-release pellet capsule and a preparation method thereof. The nifedipine pellet is prepared from nifedipine, a hydrophilic swelling carrier, a hydrophobic structure framework material, an interface stabilizer, namely hydrophobic fumed silica, and a solubilizer. A step-by-step pre-dispersion and hot-melt co-extrusion combined process is adopted, a modified lipid intermediate containing an interface stabilizer is firstly prepared, and then the modified lipid intermediate and a drug-containing hydrophilic premix are co-extruded. According to the method, an interface pinning effect is generated by utilizing enrichment of an interface stabilizer on a two-phase interface, and a stable microcosmic bicontinuous phase skeleton structure is constructed. The structure utilizes the physical barrier and zigzag pore effect of the lipid skeleton, and can realize zero-order stable release of the drug without coating. The problems of burst release risk and ethanol-induced dosage dumping of a traditional preparation are effectively solved, the process is continuous and efficient, and the product reproducibility is good.

A duloxetine enteric-coated pellet, a compound formulation and a preparation method therefor. The duloxetine enteric-coated pellet comprises a drug-containing pellet and an enteric layer, wherein the enteric layer contains hydroxypropyl methylcellulose phthalate (HPMCP), the mass ratio of HPMCP to the enteric layer is 55.6-90.9%, the enteric layer can be dissolved in a medium having a pH value of 5.5 or above, and the weight gain of the enteric layer is 12% or more. By means of optimization of the type of materials preventing ethanol-induced dose dumping and the thickness of the enteric layer, HPMCP is selected as an enteric material for preventing ethanol-induced dose dumping, so that the duloxetine enteric-coated pellet has both good preventing effect on ethanol-induced dose dumping and ideal dissolution speed.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This invention discloses a briceceran sustained-release tablet and its preparation method, belonging to the field of pharmaceutical formulations. This invention aims to solve the problems of food effect, release instability, and processability issues associated with briceceran sustained-release tablets. Technical solution: A tablet-within-a-tablet structure is adopted, with the sustained-release core containing a composite hydroxypropyl methylcellulose (high / medium viscosity mixture) and micronized ethyl cellulose, and the immediate-release outer layer containing a disintegrant; the preparation includes ethanol granulation and compression steps. Technical effects: Achieves stable drug release over 24 hours, with a postprandial / fasting release difference of <3%, avoiding dose dumping, while improving flowability and hardness by 53%, suitable for industrial production.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention discloses a briracetam sustained-release tablet and a preparation method thereof, belongs to the field of pharmaceutical preparations, and aims to solve the problems of food effect, unstable release and process formability of the briracetam sustained-release tablet. According to the technical scheme, a tablet-in-tablet structure is adopted, a sustained-release core contains composite hydroxypropyl methylcellulose (high / medium viscosity mixture) and micronized ethyl cellulose, and a quick-release outer layer contains a disintegrating agent; the preparation method comprises the steps of ethanol granulation and pressing. The invention has the technical effects that the 24-hour stable drug release is realized, and the postprandial / empty stomach release difference is 1t; and meanwhile, the flowability and the hardness are improved by 53%, and the preparation method is suitable for industrial production.